abs177.txt	tumor	antigen	heterogeneity	limits	success	of	chimeric	receptor	(car)t-cell	therapies		embryonal	carcinomas	(ec)	and	mixed	testicular	germ	cell	tumors(tgct)	containing	ec	which	are	the	most	aggressive	tgct	subtypes	useful	fordissecting	this	issue	as	ecs	express	cd30	but	also	contain	cd30-/dimcells	we	found	that	cd30-redirected	car	t	cells	(cd30	cells)	exhibitantitumor	activity	in	vitro	against	human	lines	tera-1	tera-2	andnccit	putative	stem	identified	by	hoechst	dye	staining	cytolyticactivity	was	complemented	their	sustained	proliferationand	proinflammatory	cytokine	production	demonstratedantitumor	an	vivo	xenograft	nod/scid/γcnull	(nsg)	mouse	model	ofmetastatic	observed	while	targeting	cd30+	tumorcells	through	(i	e	antigen-dependent	targeting)	eliminatedsurrounding	cd30-	antigen-independent	manner	via	a	cell-cellcontact-dependent	fas/fasl	interaction	addition	ectopic	fas	(cd95)expression	fas-	sufficient	to	improve	t-cell	antitumoractivity	overall	these	data	suggest	might	be	animmunotherapy	for	additionally	between	andcar	can	exploited	reduce	escape	due	heterogeneous	antigenexpression	or	antitumor	cancer	immunol	res	6(10)	1274-87	©2018	aacr
